SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-001286
Filing Date
2023-02-14
Accepted
2023-02-14 16:32:51
Documents
66
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20221231x10q.htm   iXBRL 10-Q 1211525
2 EX-10.1 otlk-20221231xex10d1.htm EX-10.1 26777
3 EX-31.1 otlk-20221231xex31d1.htm EX-31.1 9606
4 EX-31.2 otlk-20221231xex31d2.htm EX-31.2 12102
5 EX-32.1 otlk-20221231xex32d1.htm EX-32.1 9511
  Complete submission text file 0001558370-23-001286.txt   6204608

Data Files

Seq Description Document Type Size
6 EX-101.SCH otlk-20221231.xsd EX-101.SCH 41393
7 EX-101.CAL otlk-20221231_cal.xml EX-101.CAL 45749
8 EX-101.DEF otlk-20221231_def.xml EX-101.DEF 210377
9 EX-101.LAB otlk-20221231_lab.xml EX-101.LAB 349342
10 EX-101.PRE otlk-20221231_pre.xml EX-101.PRE 325851
60 EXTRACTED XBRL INSTANCE DOCUMENT otlk-20221231x10q_htm.xml XML 1137789
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 23630307
SIC: 2836 Biological Products, (No Diagnostic Substances)